Public Sector Pension Investment Board Makes New Investment in ADMA Biologics, Inc. (NASDAQ:ADMA)

Public Sector Pension Investment Board purchased a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 494,500 shares of the biotechnology company’s stock, valued at approximately $9,885,000. Public Sector Pension Investment Board owned about 0.21% of ADMA Biologics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Quest Partners LLC bought a new stake in ADMA Biologics during the 2nd quarter worth about $29,000. Hollencrest Capital Management acquired a new stake in shares of ADMA Biologics during the 3rd quarter worth approximately $30,000. Larson Financial Group LLC bought a new stake in shares of ADMA Biologics during the third quarter worth approximately $31,000. Harvest Fund Management Co. Ltd acquired a new position in ADMA Biologics in the third quarter valued at approximately $62,000. Finally, CWM LLC boosted its stake in ADMA Biologics by 114.2% in the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after acquiring an additional 4,367 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Insider Buying and Selling

In related news, Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the transaction, the director now directly owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. This represents a 5.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Brad L. Tade sold 15,000 shares of the firm’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the transaction, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at $4,218,007.95. This represents a 7.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.70% of the stock is owned by corporate insiders.

Analyst Ratings Changes

ADMA has been the subject of several recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a research report on Friday, September 20th. Raymond James increased their target price on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research note on Friday, November 8th. Finally, HC Wainwright raised their target price on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, November 8th.

ADMA Biologics Price Performance

Shares of ADMA stock opened at $21.83 on Friday. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a 12-month low of $3.60 and a 12-month high of $23.64. The firm has a fifty day moving average of $19.08 and a 200-day moving average of $15.23. The firm has a market capitalization of $5.16 billion, a price-to-earnings ratio of 77.96 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. The firm had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same quarter in the previous year, the firm posted $0.01 earnings per share. On average, equities research analysts forecast that ADMA Biologics, Inc. will post 0.52 earnings per share for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.